Cadrenal develops novel and differentiated biopharmaceutical products to bridge essential gaps in currently available anticoagulation therapeutics. The company's 12-LOX inhibitor portfolio represents a differentiated platform approach across a range of thrombotic and inflammatory conditions, with both acute and chronic potential applications.
Cyborg Score Rationale
With a market capitalization of $19.41 million, Cadrenal is a small-cap biotech entity with no revenue and negative earnings per share of -8.76. An End-of-Phase 2 meeting for CAD-1005 is scheduled this month (March 2026), potentially validating its 12-LOX inhibitor platform. The company exhibits clinical promise but faces typical biotech development risks and limited financial resources.
Top Insights
Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia demonstrated a reduction in thrombotic events on a background of standard anticoagulants.
The broader pipeline includes tecarfarin (Phase 3-ready vitamin K antagonist) and frunexian (parenteral Factor XIa inhibitor for acute hospital settings).
Institutional ownership is relatively low at 5.2%, while insider ownership is significant at 38.6%, reflecting confidence from those closest to the company.
Analyst targets suggest a potential upside with a target price of $34.
Named Competitors
Warfarin — Traditional oral anticoagulant with narrow therapeutic window
Eliquis (apixaban) — DOAC with limited efficacy in kidney disease patients
Xarelto (rivaroxaban) — DOAC with limited efficacy in kidney disease patients
Recent Developments
(March 2026) End-of-Phase 2 meeting scheduled for CAD-1005 in heparin-induced thrombocytopenia
(March 2026) Expanded pipeline with acquisition of selective 12-LOX inhibitors including oral candidates
(December 2025) Continued advancement of tecarfarin for patients with end-stage kidney disease and left ventricular assist devices
Open the full interactive Cadrenal Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.